Komori
Alfresa Holdings (2784) · InitiativeRestated

Preventing recurrence of improper prescription reimbursement claims

First written in FY2021-Q1. 3 of 4 entries say "Restated". Latest entry: FY2021.

4entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2021-Q1 – FY20212020: 220202021: 22021
Same theme, other companies
Recurrence prevention following inappropriate conduct in claims for prescription dispensing feesA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2021RestatedAnnual report

    「To thoroughly implement measures to prevent a recurrence of the improper conduct related to dispensing fee claims discovered during the previous fiscal year, the Company introduced new management software and took measures including appropriate personnel allocation.」

    As measures to prevent recurrence of improper prescription reimbursement claims, the Company continues to introduce management software and maintain appropriate staffing.
  2. FY2021-Q3RestatedAnnual report

    「To thoroughly implement measures to prevent a recurrence of the improper conduct related to dispensing fee claims discovered during the previous fiscal year, the Company introduced new management software and took measures including appropriate personnel allocation.」

    As measures to prevent recurrence of improper prescription reimbursement claims, the Company continues to introduce management software and maintain appropriate staffing.
  3. FY2021-Q2RestatedAnnual report

    「To thoroughly implement measures to prevent a recurrence of the improper conduct related to dispensing fee claims discovered during the previous fiscal year, the Company introduced new management software and took measures including appropriate personnel allocation.」

    As measures to prevent recurrence of improper prescription reimbursement claims, the Company continues to introduce management software and maintain appropriate staffing.
  4. FY2021-Q1First statedAnnual report

    「To thoroughly implement measures to prevent a recurrence of improper conduct relating to dispensing-fee claims discovered in the previous consolidated fiscal year, the Company has taken measures including introducing new management software and arranging appropriate staffing.」

    In response to improper prescription reimbursement claims, the Company has introduced new management software and implemented preventive measures, including appropriate staffing, to prevent recurrence.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Alfresa Holdings yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.